GÖKHAN BURUL

Dr. GÖKHAN BURUL

orcid

Research Focus & Metrics

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMelek Yalcin Mutlu
Melek Yalcin Mutlu
OIOzan Cemal Icacan
Ozan Cemal Icacan
FYFatih Yıldırım
Fatih Yıldırım
ATAlp Temiz
Alp Temiz
FFFilippo Fagni
Filippo Fagni
CBCemal Bes
Cemal Bes
Background: The accruing evidence about the efficacy of anti-IL-1 agents in Familial Mediterranean Fever (FMF) patients led to their widespread off-label use. Therefore, identifying precise indications and clinical characteristics of IL-1i-warranting patients are important. This study investigated the clinical characteristics and treatment indications of patients with FMF requiring interleukin 1 inhibition therapy (IL-1i). Methods: Hospital records of FMF patients attending a tertiary care center at the Department of Rheumatology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital were retrospectively analyzed. Data on symptoms and disease manifestations, age of symptom onset, time to diagnosis, MEFV variants, type of treatment, and their indications were collected. Results: Between June 2020 and March 2023, 312 FMF patients were identified. The mean age at the onset of symptoms was 14.0, and the mean time to diagnosis was 11.9 years. In total, 87.1% of patients were receiving colchicine monotherapy, while the remaining 11.8% warranted IL-1i. Clinical symptoms and flare manifestations did not show a significant difference between the two groups. However, patients receiving IL-1i started having symptoms at younger age (11.5 vs. 14.5, p = 0.042) and time to diagnosis was longer (18.2 vs. 11.0, p < 0.01). M694V homozygosity was more common in patients receiving IL-1i. Indications for patients receiving IL-1i were colchicine resistance (8.0%), secondary amyloidosis (5.1%), and colchicine intolerance (2.2%). Conclusions: This study shows that a subset of FMF patients, particularly those with a more severe phenotype with an earlier disease onset and M694V homozygosity, require IL-1i treatment despite the overall good efficacy and tolerability of colchicine, primarily due to colchicine resistance, intolerance, or complications such as amyloidosis.

13 January 2026 in Transplant Infectious Disease
Verified
Journal Article
Closed access
GBGÖKHAN BURUL
GÖKHAN BURUL
BTBüşra Tuğçe Tonyalı
Büşra Tuğçe Tonyalı
ISİsTemi Serin
İsTemi Serin

6 October 2026 in Journal of Hematopathology
Verified
Journal Article
Closed access
PDF file
GBGÖKHAN BURUL
GÖKHAN BURUL
ÇKÇagla Karaoglan
Çagla Karaoglan
EBErdem Bektaş
Erdem Bektaş
CBCemal Bes
Cemal Bes
LKLeylagül Kaynar
Leylagül Kaynar
ŞÖŞeniz Öngören
Şeniz Öngören

25 July 2026 in Journal of Hematopathology
Verified
Journal Article
Closed access
PDF file
GBGÖKHAN BURUL
GÖKHAN BURUL
BTBüşra Tuğçe Tonyalı
Büşra Tuğçe Tonyalı
IYİsA Yalçınkaya
İsA Yalçınkaya
SBSena Beyazyıldırım
Sena Beyazyıldırım
MIMerve İnCeman
Merve İnCeman
ISİsTemi Serin
İsTemi Serin

Verified
Journal Article
Open access
PDF file
TCTahir Alper Cinli
Tahir Alper Cinli
GBGÖKHAN BURUL
GÖKHAN BURUL
HGHasan GÖZE
Hasan GÖZE
MAMesut Ayer
Mesut Ayer
ISIstemi Serin
Istemi Serin
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Despite advances in immunochemotherapy, approximately 30–40% of patients experience relapsed or refractory disease. Nutritional and inflammatory status, reflected by composite indices, may independently influence clinical outcomes. However, the prognostic value of the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), and Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score has not been well established in DLBCL patients treated with rituximab-based regimens. Methods: We retrospectively analyzed 192 patients with newly diagnosed DLBCL who received at least three cycles of R-CHOP or R-EPOCH at Başakşehir Çam and Sakura City Hospital between January 2020 and January 2026. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal cutoff values. Kaplan–Meier analysis with log-rank testing and univariable/multivariable Cox proportional hazards regression analyses were used to evaluate the prognostic impact of the PNI, GNRI, and HALP on overall survival (OS) and progression-free survival (PFS). Results: Among the six indices evaluated (PNI, GNRI, HALP, SII, ALI, and CAR), the PNI demonstrated the highest discriminatory ability for OS (AUC = 0.734, p = 0.001), followed by the HALP (AUC = 0.671, p = 0.020) and GNRI (AUC = 0.668, p = 0.022). The optimal cutoff values were ≤46.45 for the PNI, ≤46.91 for the GNRI, and ≤223.95 for HALP. Low values of all three indices were significantly associated with elevated LDH levels, advanced Ann Arbor stage, and higher IPI category. Kaplan–Meier analysis demonstrated significantly inferior OS in the low PNI (52.8 ± 2.6 vs. 67.1 ± 1.2 months, p = 0.001), low GNRI (49.5 ± 3.1 vs. 66.0 ± 1.4 months, p = 0.001), and low HALP (58.8 ± 2.8 vs. 64.9 ± 1.2 months, p = 0.005) groups. In separate multivariable Cox models adjusted for sex and IPI, the PNI (HR = 0.216, p = 0.009), HALP (HR = 0.276, p = 0.031), and GNRI (HR = 0.294, p = 0.011) remained independently associated with OS. No significant association was observed between these indices and PFS. Conclusions: The PNI, GNRI, and HALP are independent prognostic markers in patients with DLBCL treated with rituximab-based regimens. These readily available and inexpensive baseline indices may complement the IPI in identifying patients at higher risk of adverse outcomes and support risk stratification at diagnosis.

4 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HGHasan GÖZE
Hasan GÖZE
IPİsmail Eren Polat
İsmail Eren Polat
NBNermin Bal
Nermin Bal
IYİsa Yalçınkaya
İsa Yalçınkaya
GBGÖKHAN BURUL
GÖKHAN BURUL
ISİstemi Serin
İstemi Serin
Background/Objectives: Interim 18F-FDG PET/CT is the most powerful prognostic tool in Hodgkin lymphoma but is only available after 2 cycles and does not guide initial treatment. The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel composite index of inflammation, nutrition, and immunity, measurable at diagnosis, but has not been studied in Hodgkin lymphoma (HL). We tested whether baseline CALLY could predict interim PET response and survival and whether combining the two provides additional information over either alone. Methods: A retrospective study of 180 consecutive patients with newly diagnosed Hodgkin lymphoma at a single center was performed. CALLY was defined as albumin (g/L) × lymphocytes (×109/L)/CRP (mg/L). Interim PET after two cycles was scored using the Deauville scale (4–5 positive). The endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median follow-up was 30.5 months, 32 patients had a PFS event, and 16 died. Interim PET was positive in 31/163 patients (19.0%). Baseline CALLY was lower in PET-positive patients compared with PET-negative patients (median 1.16 vs. 3.34; p = 0.022; area under the curve 0.635, modest discrimination). Interim PET positivity (29.8% vs. 13.0%; OR 2.84, 95% CI 1.26–6.42), 24-month PFS (66.9% vs. 89.8%; p = 0.001) and OS (84.8% vs. 95.5%; p = 0.022) were reduced below a Youden-derived threshold of 1.5. CALLY was not independently prognostic after adjustment for interim PET (PFS hazard ratio [HR] 1.86, 95% CI 0.79–4.37; p = 0.157). A three-tier exploratory model combining both factors separated 24-month PFS into 94.5% (n = 87), 79.6% (n = 53), and 41.2% (n = 17) (p < 0.001; high- vs. low-risk HR 9.48, 95% CI 3.59–25.04), although the intermediate tier was not statistically different from the low-risk tier. Conclusions: In this cohort, baseline CALLY provides a low-cost pre-treatment correlate of early metabolic response and outcome, with numerically greater discrimination than the International Prognostic Score. Its prognostic signal seems largely mediated through the interim PET response, and therefore it should complement, not replace, interim response assessment. Discrimination was modest, and the integrated model is exploratory and requires prospective multicenter validation in contemporary protocols before clinical use.